Circulating histocompatibility antigen (HLA) gene products may help differentiate benign from malignant indeterminate pulmonary lesions

Autor: Gabriela C. Lobato, Michael J. Liptay, Melissa R. Pergande, Smriti Kanangat, Cristina Fhied, Jeffrey A. Borgia, Maryam F. Raouf, Christopher W. Seder
Rok vydání: 2018
Předmět:
Male
0301 basic medicine
Lung Neoplasms
Immunology
Human leukocyte antigen
Major histocompatibility complex
Sensitivity and Specificity
Article
Cohort Studies
Diagnosis
Differential
Lesion
03 medical and health sciences
0302 clinical medicine
Antigen
HLA Antigens
Carcinoma
Non-Small-Cell Lung
Cell Line
Tumor
Biomarkers
Tumor
medicine
Humans
Immunology and Allergy
Early Detection of Cancer
Aged
Aged
80 and over
Lung
biology
business.industry
Histocompatibility Antigens Class I
Histocompatibility Antigens Class II
General Medicine
Middle Aged
medicine.disease
Histocompatibility
030104 developmental biology
medicine.anatomical_structure
030220 oncology & carcinogenesis
biology.protein
Cancer research
Multiple Pulmonary Nodules
Adenocarcinoma
Biomarker (medicine)
Female
medicine.symptom
business
Zdroj: Hum Immunol
ISSN: 0198-8859
DOI: 10.1016/j.humimm.2018.04.003
Popis: BACKGROUND: This study explores the potential diagnostic utility of soluble Human Leukocyte Antigen (sHLA) molecules differentially released by lung adenocarcinoma and benign lung lesions. METHODS: Conditioned media from the NSCLC cell lines H358 and H1703 were immunoblotted for soluble isoforms of major histocompatibility complex (MHC) class I (ABC) and II (DRB1, DMB, and DQ) antigens. Sera from 25 patients with benign and 25 patients with malignant lesions were similarly evaluated to appraise the potential diagnostic value. RESULTS: Higher concentrations of soluble HLA class I molecules were observed in conditioned medium for the highly-invasive H1703 cell line, relative to the more indolent H358 cells. Evaluation of these markers against a cohort of 50 cases demonstrated that patients with malignant lesions possess higher levels of HLA class I and II molecules relative to those with benign lesions (p < 0.05), with exception to the primary isoform, DQA1, which was suppressed in malignancies. An analysis of biomarker performance via ROC analysis revealed promising performance (AUC > 0.75) for DMB and the 26 kDa isoform of DQ in distinguishing lesion pathology. CONCLUSIONS: Soluble HLA molecules may have diagnostic value for early-stage NSCLC. Validation studies are currently underway using sera from a lung cancer screening cohort.
Databáze: OpenAIRE
Externí odkaz: